837430-11-2

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 837430-10-1 (2R,5S)-2,5-dihydro-3,6-dimethoxy-2-[(2',5'-difluorophenyl)methyl]-5-isopropylpyrazine 
• 923601-71-2 2-tert-butoxycarbonylamino-3-(2,5-difluorophenyl)-acrylic acid methyl ester 
• 85117-99-3 2-(bromomethyl)-1,4-difluorobenzene 

Downstream Products

• 261380-31-8 (R)-N-(1,1-dimethylethoxycarbonyl)-2,5-difluorophenylalanine 
• 837430-12-3 (R)-3-[(1,1-dimethylethoxycarbonyl)amino]-1-diazo-4-(2,5-difluorophenyl)butan-2-one 
• 486459-98-7 (3R)-3-[(1,1-dimethylethoxycarbonyl)amino]-4-(2,5-difluorophenyl)butanoic acid 
• 837430-13-4 (3R)-3-[(1,1-dimethylethoxycarbonyl)amino]-4-(2,5-difluorophenyl)butanoic acid methyl ester 
• 486460-31-5 7-[(3R)-3-amino-4-(2,5-difluorophenyl)butanoyl]-3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazine 
• 486460-22-4 7-[(3R)-3-[(1,1-dimethylethoxycarbonyl)amino]-4-(2,5-difluorophenyl)butanoyl]-3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazine 
• 1026406-69-8 {1-(2,5-difluoro-benzyl)-3-oxo-3-[3-(2,2,2-trifluoro-ethyl)-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-propyl}-carbamic acid tert-butyl ester 
• 923563-75-1 [(R)-2-(2,5-difluoro-phenyl)-1-(methoxy-methyl-carbamoyl)-ethyl]-carbamic acid tert-butyl ester 
• 923564-18-5 [(R)-3-(3-tert-butylcarbamoyl-6-trifluoromethyl-pyridin-2-yl)-1-(2,5-difluoro-benzyl)-2-oxo-propyl]-carbamic acid tert-butyl ester 
• 923564-19-6 [(1R,2S)-3-(3-tert-butylcarbamoyl-6-trifluoromethyl-pyridin-2-yl)-1-(2,5-difluoro-benzyl)-2-hydroxy-propyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

1-AMINO LINKED COMPOUNDS

The present invention is directed to compounds of formula (I): or a pharmaceutically acceptable salt thereof; wherein A is (II); X is selected from CH, CF and N, R8 is selected from H, C1-C6 alkyl, aryl, heteroaryl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, C2-C6 alkyl-O- C1-C6 alkyl, C1-C6 haloalkyl, hydroxy C2-C6 alkyl, -C(O)R9 and -SO2R9, or R7 and R8 combine to form (III), (IV); W is selected from CRlO and CR15, RlO is selected from H, halo, -C(O)NR13R14, C1-C6 alkyl, aryl, heteroaryl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, C1-C6 alkyl-O- C1-C6 alkyl and hydroxy C1-C6 alkyl; Het is a N-linked 5-membered heteroaryl ring optionally substituted with 1-3 substituents selected from methoxy, Cl, F, CH3, CF3, aryl, heteroaryl, C1-C4 alkylaryl or C1-C4 alkylheteroaryl, for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes.

PHENYL COMPOUNDS

The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (xx) ; X is selected from CH, CF and N, R5 is selected from H, C1-C6 alkyl, C1-C6 fluoroa

PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS

The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (1); X is selected from CH, CF and N; R5 is selected from H, C1-C6 alkyl, C1-C6 fluoroalk

(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

A novel series of β-amino amides incorporating fused heterocycles, i.e., triazolopiperazines, were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of type 2 diabetes. (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl]-1-(2,4,5-trifluorophenyl)butan-2-amine (1) is a potent, orally active DPP-IV inhibitor (IC50 = 18 nM) with excellent selectivity over other proline-selective peptidases, oral bioavailability in preclinical species, and in vivo efficacy in animal models. MK-0431, the phosphate salt of compound 1, was selected for development as a potential new treatment for type 2 diabetes.